1. Home
  2. S vs GKOS Comparison

S vs GKOS Comparison

Compare S & GKOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo SentinelOne Inc.

S

SentinelOne Inc.

HOLD

Current Price

$17.03

Market Cap

5.4B

Sector

Technology

ML Signal

HOLD

Logo Glaukos Corporation

GKOS

Glaukos Corporation

HOLD

Current Price

$139.45

Market Cap

6.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
S
GKOS
Founded
2013
1998
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Medical/Dental Instruments
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.4B
6.0B
IPO Year
2021
2015

Fundamental Metrics

Financial Performance
Metric
S
GKOS
Price
$17.03
$139.45
Analyst Decision
Buy
Strong Buy
Analyst Count
31
12
Target Price
$19.28
$126.92
AVG Volume (30 Days)
6.7M
997.9K
Earning Date
05-27-2026
04-29-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,001,278,000.00
$507,442,000.00
Revenue This Year
$22.84
$23.32
Revenue Next Year
$17.32
$27.43
P/E Ratio
N/A
N/A
Revenue Growth
21.89
32.33
52 Week Low
$11.81
$73.16
52 Week High
$21.40
$148.11

Technical Indicators

Market Signals
Indicator
S
GKOS
Relative Strength Index (RSI) 61.20 61.05
Support Level $16.28 $130.04
Resistance Level $17.18 $147.43
Average True Range (ATR) 0.69 5.14
MACD 0.18 1.82
Stochastic Oscillator 90.22 77.50

Price Performance

Historical Comparison
S
GKOS

About S SentinelOne Inc.

SentinelOne is a cloud-based cybersecurity company specializing in endpoint protection. SentinelOne's primary offering is its Singularity platform that offers a single pane of glass for an enterprise to detect and respond to security threats attacking its IT infrastructure. The California-based firm was founded in 2013 and went public in 2021.

About GKOS Glaukos Corporation

Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.

Share on Social Networks: